Meine TRADING-WELT

Nexter Kandidat für mein Trading Depot

RCKT - Rocket Pharmaceuticals, Inc.



Rocket Pharmaceuticals, Inc.
Next Catalyst

RCKT RP-L102 in FA 1H 2020 and 2H 2020 Follow up on phase 1 process B data
RP-L102 in FA 2H 2020 Preliminary phase 2 data
RP-A501 in Danon Disease 2H 2020 Initial phase 1 data (low and high dose, safety and efficacy), initiate pediatric dosing, initiate phase 2 registration enabling study
RP-A501 in Danon Disease 2021 More mature phase 1 results
RP-L201 in LAD-I 1H 2020 and 2H 2020 Follow up results
RP-L301 in PKD 2H 2020 Clinical data from phase 1 trial
RP-L401 in IMO 2020 Initiation of phase 1 study

Schon im Depot

Clearside Biomedical, Inc.





Next Catalyst

XIPERE
Q2 2020
NDA resubmission

RGX-314 suprachoroidal
1H 2020
Begin phase 2 trial in wet AMD

RGX-314 suprachoroidal
2H 2020
Begin phase 2 trial in diabetic retinopathy

RGX-314 suprachoroidal
2021
Interim phase 2 data for wet AMD and diabetic retinopathy phase 2 studies

Bausch Health Partnership
2020
Plans for XIPERE development in additional indications, additional candidates using SCS Microinjector system

Aura Biosciences
2020
Updates for development plans using SCS Microinjector system to treat choroidal melanoma

Additional Collaborations
Near to Medium Term
Other gene therapy and ophthalmology companies could collaborate to utilize SCS Microinjector system for various applications

CLS-AX
Mid 2020
IND submission for treating wet AMD (twice yearly treatment would be significantly differentiated)